Gut-Brain Axis (장뇌축) — 2026-05-21

🔬 Latest Research Highlights

Predicting Alzheimer’s Risk with AI, Diet, and Gut Microbiome

• Research Team: Reported by Athens Times (2026-05-21, 18 hours ago)
• Key Findings: A new approach uses AI to predict Alzheimer’s risk by analyzing dietary patterns and gut health. Unlike invasive tests, this method utilizes simple questionnaires to improve prediction. The study reaffirmed the strong link between fiber intake, microbiome diversity, and the maintenance of cognitive function.
• Significance: By enabling early screening based on diet and gut health data without the need for blood tests or brain imaging, this could become a widely applicable screening tool, even in medical environments with limited resources.

Coffee Reshapes Both the Gut and Brain

• Research Team: Reported by ScienceDaily (2026-05-17, 4 days ago)
• Key Findings: Both caffeinated and decaffeinated coffee were shown to shift gut bacterial composition in ways linked to improved mood and reduced stress. Notably, decaf coffee showed benefits in learning and memory, while caffeinated coffee was associated with improved focus and reduced anxiety.
• Significance: This suggests that coffee’s effect on brain function isn't just about caffeine, but also pathways involving gut microbial changes. This could spur further research into coffee as a dietary strategy for mental health interventions.

2 sources

sciencedaily.com

sciencedaily.com

sciencedaily.com

sciencedaily.com

The Brain-Gut-Skin Axis: A New Paradigm for Chronic Skin Diseases

• Research Team: Reported by AJMC (2026-05-20, 1 day ago)
• Key Findings: Chronic skin conditions like atopic dermatitis and psoriasis are now understood as systemic diseases linked by the brain-gut-skin axis. A mechanism has been identified where gut microbiome imbalances influence the skin and brain simultaneously through inflammatory signals.
• Significance: This provides clinical evidence that an integrative approach, combining dermatological treatment with gut microbiome management, can enhance the effectiveness of treatments for chronic skin diseases.

💊 Clinical Trials & Drug Trends

• Microbiome Drugs, from Wellness to Clinical: Trial results show that gut bacteria can help some melanoma patients overcome immunotherapy resistance. According to Longevity Technology (2026-05-19, 2 days ago), microbiome-based drugs are moving beyond supplements and health foods to become serious auxiliary tools for cancer immunotherapy. A specific cluster of about 50 bacteria extracted from a patient's stool has notably induced immunotherapy responses in advanced colon cancer patients.

• Psychobiotics Human Clinical Trial Review: Frontiers in Microbiology (March 2026) published a comprehensive analysis of human clinical trials evaluating mental health improvements via the gut-brain axis. Lactobacillus and Bifidobacterium probiotics showed significant effects in relieving anxiety and depression, though standardizing strain selection, dosage, and duration remains a challenge.

🏢 Industry & Business

• Kanvas Biosciences Raises $48 Million Series A: Spatial biology-based microbiome therapeutics developer Kanvas Biosciences completed a $48 million Series A funding round (May 2026). The company focuses on developing gut microbiome therapies for cancer patients, with its core technology based on a cluster of over 50 bacteria identified in the stool of healthy cancer survivors.

• Nestlé Joins the Microbiome Therapeutics Innovation Group (MTIG): Global food giant Nestlé joined MTIG (April 2026), an independent coalition aimed at advancing FDA-approved microbiome therapies. The entry of a major food and nutrition company into the microbiome therapy ecosystem is accelerating the convergence of industry boundaries.

🧠 Deep Dive: How Coffee Simultaneously Changes the Gut and Brain

While it is well known that coffee affects mood and cognitive function, the latest research reveals that a significant portion of this pathway occurs through the gut-brain axis.

Beyond its stimulant effect from blocking adenosine receptors, caffeine also alters the composition of the gut microbiota. Studies show that coffee consumption (caffeinated or decaf) increases beneficial bacteria like Bifidobacterium and Lactobacillus. These bacteria produce short-chain fatty acids (SCFAs) and serotonin precursors, which send signals to the brain via the vagus nerve, leading to mood stabilization and reduced anxiety.

Interestingly, decaffeinated coffee also improved brain functions related to learning and memory. This means that components in coffee like polyphenols can exert independent neuroprotective effects via gut microbes. The remaining question is precisely which coffee components work through which strains and neural circuits.

📋 Action Guide

1. Drink Coffee Consistently, But Not in Excess: Both caffeinated and decaf coffee appear to increase beneficial gut bacteria. 1–2 cups a day can contribute to gut-brain axis health. However, consider individual sensitivity, as excessive caffeine can worsen anxiety.

2. Boost Alzheimer’s Prevention with Fiber: AI-based research confirms that a fiber-rich diet and microbiome diversity are key protective factors. Including whole grains, beans, and vegetables in every meal increases SCFA production, helping suppress neuroinflammation.

3. Check Your Gut Health for Chronic Skin Troubles: Research on the brain-gut-skin axis shows that skin inflammation (atopy, psoriasis) can be linked to gut microbiome imbalances. Regularly consuming probiotic foods (yogurt, kimchi, doenjang) can improve your gut environment and help alleviate skin symptoms.

4. Focus on the Microbiome if Undergoing Immunotherapy: Latest clinical studies show that gut bacterial composition directly affects immunotherapy response rates. Avoid unnecessary antibiotics and maintain a plant-based diet to protect microbiome diversity. Consider discussing microbiome management with your doctor before treatment.

👀 Key Points to Watch

• Psychobiotic Standardization: Results are currently difficult to compare due to varying strains, dosages, and durations. Watch for standardized multi-center trial results expected in the second half of 2026.

• Expansion of Microbiome × Immunotherapy Trials: Several startups, including Kanvas Biosciences, are preparing Phase 2 trials for microbiome therapies used in combination with immuno-oncology drugs. Interim data is expected in late 2026, which may lead to FDA fast-track consideration.

• Competitive Race for Brain-Gut-Skin Axis Therapies: Multiple clinical trials are being designed in this new therapeutic field where dermatology, neurology, and gastroenterology intersect. Initial results for probiotic combination therapy trials targeting atopic dermatitis are expected within the year.